Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Olympic-ro 33, Seoul, 05505, Republic of Korea.
Division of Neuroradiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Eur Radiol. 2021 Jul;31(7):5289-5299. doi: 10.1007/s00330-020-07467-4. Epub 2021 Jan 6.
To evaluate the diagnostic performance of the T2-FLAIR mismatch sign for prediction of isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted lower-grade gliomas (LGGs) and review studies with false positive results.
The MEDLINE and EMBASE databases were searched up to March 13, 2020, to identify articles reporting the diagnostic performance of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted LGGs (IDHmut-Noncodel) using the search terms (T2 FLAIR mismatch). Pooled sensitivity, specificity, and correlation coefficient for interobserver agreement were calculated.
Twelve studies including a total of 1053 patients were included. The median age was 43 (median; range, 14-56). The pooled sensitivity and specificity were 42% (95% CI, 28-58%) and 100% (95% CI, 88-100%), respectively. According to the HSROC curve, the area under the curve was 0.77 (95% CI, 0.73-0.80). Considerable heterogeneity was possible among the studies in terms of both sensitivity and specificity. A threshold effect was suggested and was considered to explain most of the heterogeneity. Four studies reported false positive results for the T2-FLAIR mismatch sign, including dysembryoplastic neuroepithelial tumor, pediatric-type gliomas, and non-neoplastic lesions. The 2 original articles with false positive results showed the highest sensitivities among the 10 studies included in the quantitative analysis, supporting the probability of the threshold effect. The pooled correlation coefficient was 0.87 (95% CI, 0.73-0.94).
The T2-FLAIR mismatch sign had a high specificity and interobserver agreement for the prediction of IDHmut-Noncodel. However, the sign demonstrated low sensitivity, and a few studies with false positive cases were also reported.
• The pooled sensitivity and specificity of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas were 42% and 100%, respectively. • Four studies reported false positive results. • The pooled correlation coefficient was 0.87, suggesting almost perfect interobserver agreement.
评估 T2-FLAIR 不匹配征象对预测异柠檬酸脱氢酶(IDH)突变、1p/19q 非缺失型低级别胶质瘤(LGGs)的诊断性能,并对存在假阳性结果的研究进行综述。
检索 MEDLINE 和 EMBASE 数据库,检索时间截至 2020 年 3 月 13 日,使用检索词(T2 FLAIR mismatch)检索报告使用 T2-FLAIR 不匹配征象预测 IDH 突变、1p/19q 非缺失型 LGG(IDHmut-Noncodel)的诊断性能的文章。计算汇总的敏感性、特异性和观察者间一致性的相关系数。
纳入 12 项研究,共计 1053 例患者。患者的中位年龄为 43 岁(中位数;范围,14-56 岁)。汇总的敏感性和特异性分别为 42%(95%CI,28%-58%)和 100%(95%CI,88%-100%)。根据 HSROC 曲线,曲线下面积为 0.77(95%CI,0.73-0.80)。在敏感性和特异性方面,研究之间存在较大的异质性。提示存在阈值效应,并且认为这是大部分异质性的原因。四项研究报告了 T2-FLAIR 不匹配征象的假阳性结果,包括发育不良性神经上皮肿瘤、小儿型胶质瘤和非肿瘤性病变。纳入定量分析的 10 项研究中,有两项原始研究报告的假阳性结果显示敏感性最高,支持阈值效应的可能性。汇总的相关系数为 0.87(95%CI,0.73-0.94)。
T2-FLAIR 不匹配征象对 IDHmut-Noncodel 的预测具有较高的特异性和观察者间一致性。然而,该征象的敏感性较低,并且也有一些存在假阳性结果的研究报告。
T2-FLAIR 不匹配征象对 IDH 突变、1p/19q 非缺失型低级别胶质瘤的预测的汇总敏感性和特异性分别为 42%和 100%。
四项研究报告了假阳性结果。
汇总的相关系数为 0.87,表明观察者间一致性几乎为完美。